Drug Delivery

New Chemistry Being Developed For Delivery Of Neuroprotective Drugs

Published in Drug Week, September 14th, 2001

One approach to treating neurodegenerative disease such as Parkinson disease is to interfere with the chemistry involved. Thus, scientists study the brain's chemical pathways and try to identify potential roadblocks.

At the 222nd national meeting of the American Chemical Society, held August 26-30, 2001, in Chicago, Illinois, Virginia Tech researchers presented their advancements in the development of such roadblocks.

Monoamine oxidases (MAO) A and B and the neuronal form of nitric oxide synthase (nNOS) are two enzyme systems thought to be involved in neurodegenerative pathways in Parkinson disease. A synthetic compound which inhibits both enzymes,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-09-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry